leisure time -WSS

leisure time

author：entertainment 2025-09-05 11:24:55 - browse：17226

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： UnitedHealth wins $3.3 billion takeover of Amedisys

WSS

FDA approves Moderna’s RSV vaccine, its second licensed product

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Anthony Fauci pushes back on GOP claims during Covid hearing

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

UnitedHealth CEO's Medicaid comments send insurer stocks diving

FDA approves Moderna’s RSV vaccine, its second licensed product

leisure time

leisure time

explore

United colonoscopy coverage change 'may cost lives,' doctors say

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Alkermes shareholders re

An outdated Medicare rule harms dementia patients with anxiety

23andMe had bad news about my health. I wish a person had delivered it

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

At least 13 dead in Texas as scorching temps continue

GOP inquiry over gain

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FTC loses bid to block Novant's North Carolina hospital merger

Wikipedia

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

'Little Tech' descents on D.C., wanting a say in how AI is regulated

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Supreme Court rules employers must be more accommodating of religious observance

FDA approves Moderna’s RSV vaccine, its second licensed product

Supreme Court rules employers must be more accommodating of religious observance

knowledge

Wikipedia

hotspot

explore